论文部分内容阅读
目的探讨熊去氧胆酸(UDCA)治疗婴儿黄疸型肝炎的疗效及安全性。方法婴儿黄疸型肝炎145例,分为治疗组(83例)和对照组(62例),二组病例均予保肝及基础治疗。治疗组在此基础上,加用UDCA。比较两组治疗前后生化指标的改善程度及治疗的不良反应。结果治疗组显效、有效和无效率分别为86.75%(72例)、6.02%(5例)和6.02%(5例);而对照组分别为66.13%(41例)、14.52%(9例)和19.35%(12例)。两组显效率比较差异有统计学意义(P=0.003 1)。治疗组黄疸消退平均时间(15.45±5.61)d,对照组为(22.78±8.51)d,两组比较差异有统计学意义(P=0.00)。治疗组治疗前后生化指标(TBil、DBil、ALT、GGT、TBA)比较,P值分别为0.000、0.000、0.060 4、0.039、0.000。治疗组与对照组治疗前后下降幅度TBil分别为(108.41±78.53)μmol/L、(71.58±51.67)μmol/L,DBil为(65.53±44.78)μmol/L、(51.67±35.43)μmol/L,GGT为(54.41±21.51)U/L、(43.67±20.61)U/L,TBA为(124.41±45.53)U/L、(61.12±29.18)U/L,两组比较P值为0.001 6、0.05、0.030 7、0.000。治疗组与对照组中均未出现严重不良事件。结论熊去氧胆酸治疗婴儿黄疸型肝炎有效且安全性良好。
Objective To investigate the efficacy and safety of ursodeoxycholic acid (UDCA) in the treatment of jaundice hepatitis in infants. Methods 145 infants with jaundice hepatitis were divided into treatment group (n = 83) and control group (n = 62). Both groups were given hepatoprotective and basic treatment. The treatment group on this basis, plus UDCA. The improvement of biochemical indexes and adverse reactions of the two groups before and after treatment were compared. Results The effective rate and the ineffective rate were 86.75% (72 cases), 6.02% (5 cases) and 6.02% (5 cases) in the treatment group, while those in the control group were 66.13% (41 cases) and 14.52% (9 cases) And 19.35% (12 cases). Significant difference between the two groups was statistically significant (P = 0.003 1). The treatment group jaundice averaged (15.45 ± 5.61) d, the control group (22.78 ± 8.51) d, the difference between the two groups was statistically significant (P = 0.00). Before and after treatment, the biochemical indexes (TBil, DBil, ALT, GGT and TBA) in the treatment group were respectively 0.000, 0.000, 0.060 4, 0.039, 0.000. The TBil of the treatment group and the control group were (108.41 ± 78.53) μmol / L, (71.58 ± 51.67) μmol / L and (65.53 ± 44.78) μmol / L, The GGT was (54.41 ± 21.51) U / L, (43.67 ± 20.61) U / L, TBA was (124.41 ± 45.53) U / L, (61.12 ± 29.18) U / , 0.030 7,0.000. No significant adverse events occurred in the treatment group and the control group. Conclusion Ursodeoxycholic acid treatment of jaundice hepatitis in infants is effective and safe.